NASDAQ: ONCY · Life Sciences · 10 alerts · CIK 1129928
Share price
$0.3399Close, Nov 16
Market cap
$46.3M
Shares outstanding
136.14MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Oncolytics Biotech Inc filings on SEC EDGAR ↗
Oncolytics Biotech Inc. reported a net loss of $28.4 million for the nine months ended September 30, 2026, compared to $19.9 million in the prior year period, driven by increased R&D and G&A expenses. The company's cash position decreased to $2.4 million, leading management to issue a going concern warning as existing resources are insufficient to fund operations for the next twelve months.
Oncolytics Biotech Research Collaboration with Coherus Oncology, Inc.
Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology to evaluate pelareorep in combination with LOQTORZI (toripalimab-tpzi) for the treatment of squamous cell anal carcinoma (SCAC). The clinical study, expected to begin in Q1 2027, will target second-line patients who have progressed on standard-of-care treatments.
Oncolytics Biotech announced translational data from a Phase 1b/2 trial evaluating pelareorep in patients with relapsed/refractory multiple myeloma. Single-cell sequencing demonstrated that pelareorep engaged the immune system, remodeled the tumor microenvironment, and increased populations of CD8 effector memory T cells. The data, which showed greater T cell expansion in clinical responders, will be presented at the 68th ASH Annual Meeting.
Oncolytics Biotech announced translational data from an ongoing Phase 1/2 study of pelareorep in combination with a checkpoint inhibitor for squamous cell anal cancer (SCAC). The data showed that the treatment more than doubled immune activation levels in nearly all patients and expanded HPV-16-specific T cell clones, which was associated with tumor shrinkage and objective responses.
Oncolytics Biotech announced updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep in combination with atezolizumab for squamous cell anal cancer (SCAC). The study demonstrated a median duration of response of approximately 15 months, with 100% of responding patients surviving longer than one year, supporting a potential registration path in HPV-driven cancers.
Oncolytics Biotech announced it will present a trial-in-progress abstract and e-poster for its REO 033 study at the ESMO Congress 2026. The study is a randomized Phase 2 trial evaluating pelareorep in combination with FOLFIRI and bevacizumab for second-line treatment of RAS-mutant, microsatellite-stable metastatic colorectal cancer.
Oncolytics Biotech provided an operational update on its GOBLET Phase 1/2 study, announcing the completion of enrollment and the expected receipt of a final grant payment from the Pancreatic Cancer Action Network (PanCAN). The company expects to report final results from Cohort 4 in Q4 2026 and initial results from Cohort 5 in the first half of 2027.
Oncolytics Biotech provided an update on its intellectual property strategy, including the issuance of new method of use patents for pelareorep in several countries and plans for a 'next generation' composition of matter patent. The company aims to extend its patent protection into the late 2040s, building on existing manufacturing protection that currently runs through 2044.
Oncolytics Biotech announced the publication of preclinical data in the Proceedings of the National Academy of Sciences demonstrating that its immunotherapy candidate, pelareorep, can transform immunologically inactive liver cancer tumors into active ones. The data showed pelareorep increased CD8+ T cell density and PD-L1 expression, potentially making challenging tumor types more susceptible to checkpoint inhibitors and other immunotherapies.
Oncolytics Biotech provided an operational update on its REO 033 randomized study for colorectal cancer, noting that substantially all clinical sites are now activated and enrollment is accelerating. The company expects to report interim clinical data from Part A of the study by year-end 2026 and has aligned with the FDA on a potential registration path for accelerated approval.